MD Financial Management’s AbbVie ABBV Stock Holding History

MD Financial Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-202	Closed	-$22K	–	232
2020 Q4	$22K	Buy	+202	New	+$19.4K	﹤0.01%	75

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

MD Financial Management's ABBV Position: Q1 2021 in Review

MD Financial Management sold out of AbbVie (ABBV) in Q1 2021, closing a stake of 202 shares — an estimated $22K sold.

MD Financial Management first reported a position in ABBV in Q4 2020 and held it in 1 quarter. The position peaked at $22K in Q4 2020. 2,615 funds tracked by Wall St. Rank hold ABBV as of Q1 2021.

MD Financial Management reported no remaining AbbVie position as of Q1 2021 after selling out during the quarter.
MD Financial Management sold 202 AbbVie shares in Q1 2021, an estimated $22K.
MD Financial Management first reported a position in AbbVie in Q4 2020 and held it in 1 quarter.
MD Financial Management's AbbVie position peaked at $22K in Q4 2020.
2,615 funds tracked by Wall St. Rank held AbbVie as of Q1 2021.

Based on MD Financial Management's 13F filing for Q1 2021, filed 6 May 2021.